Pharmagreen Biotech Inc. (OTCMKTS:PHBI) has announced on September 22, 2022, about Ethan Styles joining the Pharmagreen team, as Vice President of Product Research and Development. He is a third generation Mendocino County, California legacy cannabis cultivator at Long Valley Farms.
On Thursday, PHBI stock slumped 6.52% to $0.0129 with more than 89K shares, compared to its average volume of 279.68K shares. The stock moved within a range of $0.0127 – 0.0131 after opening trade at $0.0131.
PHBI Pharmagreen Biotech Appoints Ethan Styles as Vice President of Product Research and Development
Mr. Styles utilizes veganic farming techniques to produce high quality craft products. He uses those same sustainable methods to grow a wide variety of medicinal plants and mushrooms. Ethan’s lifelong work with therapeutic plants, cannabis, medicinal plants and fungi, combined with years of personal studies in molecular biology, has provided him with keen insight into the human health benefits provided by these plants.
Mr. Styles’ expertise, along with his unique skill set will be of immense help in realizing the company’s vision of a diversified biotech organization expanding far beyond cannabis into a broad range of functional organic health products. He has vast knowledge of molecular cell biology through his ongoing graduate studies.
After brining Mr. Styles on board, Pharmagreen plans to use its in-house knowledge of veganics, organics, tissue culture (Chibafreen), good farming practices, molecular biology and genomic technologies in future production of plant and fungi biomaterial. Pharmagreen’s transgenic program uses the newest technology available to research and create nutraceuticals, protein-based formulations, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
“My aim as V. P. of Research and Development is to simplify health and wellness and give humanity the ability to experience the best out of life. Through ancient knowledge and today’s most advanced technologies, we can develop a way of life unknown to most of the population,” Mr. Styles stated. “By using multiple genomic data platforms to cross reference client-specific data against historical and current genomic patterns, we have the ability to make very direct recommendations regarding appropriate active ingredients. I look forward to leading Pharmagreen’s development of health and wellness formulations for everyone around the world.”
PHBI stock is above the 20-Day and 50-Day Moving averages of $0.0101 and $0.0091 respectively. However, the stock is trading below the 200-Day moving average of $0.0132. The company has a total market capitalization of $5.47 million.